Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

A pilot study assessing the prognostic value of CK18 and nDNA biomarkers in severe sepsis patients.

Moore DJ, Greystoke A, Butt F, Wurthner J, Growcott J, Hughes A, Dive C.

Clin Drug Investig. 2012 Mar 1;32(3):179-87. doi: 10.2165/11598610-000000000-00000.

PMID:
22217154
2.

Cell death serum biomarkers are early predictors for survival in severe septic patients with hepatic dysfunction.

Hofer S, Brenner T, Bopp C, Steppan J, Lichtenstern C, Weitz J, Bruckner T, Martin E, Hoffmann U, Weigand MA.

Crit Care. 2009;13(3):R93. doi: 10.1186/cc7923. Epub 2009 Jun 18.

3.

Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.

Linder S, Olofsson MH, Herrmann R, Ulukaya E.

Expert Rev Mol Diagn. 2010 Apr;10(3):353-9. doi: 10.1586/erm.10.14. Review.

PMID:
20370591
4.

Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.

de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, de Jong S, de Vries EG, Dive C, Gietema JA.

Neoplasia. 2008 Oct;10(10):1041-8.

5.

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.

Greystoke A, O'Connor JP, Linton K, Taylor MB, Cummings J, Ward T, Maders F, Hughes A, Ranson M, Illidge TM, Radford J, Dive C.

Br J Cancer. 2011 Feb 15;104(4):719-25. doi: 10.1038/sj.bjc.6606082. Epub 2011 Jan 18.

6.

Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.

Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M.

Int Immunopharmacol. 2009 May;9(5):645-8. doi: 10.1016/j.intimp.2009.02.004. Epub 2009 Feb 26.

PMID:
19249390
7.

Serum cytokeratin 18 as a biomarker for gastric cancer.

Oyama K, Fushida S, Kinoshita J, Okamoto K, Makino I, Nakamura K, Hayashi H, Inokuchi M, Nakagawara H, Tajima H, Fujita H, Takamura H, Ninomiya I, Kitagawa H, Fujimura T, Ohta T.

Clin Exp Med. 2013 Nov;13(4):289-95. doi: 10.1007/s10238-012-0202-9. Epub 2012 Jul 24.

PMID:
22825587
8.

Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study.

Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B.

Crit Care. 2005;9(6):R816-24. Epub 2005 Nov 15.

9.

Circulating nucleosomes as a predictor of sepsis and organ dysfunction in critically ill patients.

Chen Q, Ye L, Jin Y, Zhang N, Lou T, Qiu Z, Jin Y, Cheng B, Fang X.

Int J Infect Dis. 2012 Jul;16(7):e558-64. doi: 10.1016/j.ijid.2012.03.007. Epub 2012 May 18.

10.

Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: a prospective study.

Simopoulos C, Tsaroucha AK, Asimakopoulos B, Giatromanolaki A, Gavriilidis P, Polychronidis A, Karayiannakis A.

BMC Gastroenterol. 2008 May 6;8:14. doi: 10.1186/1471-230X-8-14.

11.

Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study.

Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Müller B.

Crit Care. 2005 Feb;9(1):R37-45. Epub 2004 Dec 17. Erratum in: Crit Care. 2005 Apr;9(2):169.

12.

Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response.

Scott LC, Evans TR, Cassidy J, Harden S, Paul J, Ullah R, O'Brien V, Brown R.

Br J Cancer. 2009 Aug 4;101(3):410-7. doi: 10.1038/sj.bjc.6605175. Epub 2009 Jul 14.

13.

Circulating apoptotic and necrotic cell death markers in patients with acute liver injury.

Craig DG, Lee P, Pryde EA, Masterton GS, Hayes PC, Simpson KJ.

Liver Int. 2011 Sep;31(8):1127-36. doi: 10.1111/j.1478-3231.2011.02528.x. Epub 2011 Apr 6.

PMID:
21745283
14.

Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C.

Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Yerci O, Oral AY, Gul CB, Gurel S, Nak SG, Gulten M.

Med Sci Monit. 2009 Apr;15(4):CR189-93.

PMID:
19333204
15.

Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients.

Ausch C, Buxhofer-Ausch V, Olszewski U, Hinterberger W, Ogris E, Schiessel R, Hamilton G.

Eur J Surg Oncol. 2009 Nov;35(11):1164-8. doi: 10.1016/j.ejso.2009.02.007. Epub 2009 Feb 28.

PMID:
19254831
16.

Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer.

Micha D, Cummings J, Shoemaker A, Elmore S, Foster K, Greaves M, Ward T, Rosenberg S, Dive C, Simpson K.

Clin Cancer Res. 2008 Nov 15;14(22):7304-10. doi: 10.1158/1078-0432.CCR-08-0111.

17.

Serum levels of caspase-cleaved cytokeratin-18 and mortality are associated in severe septic patients: pilot study.

Lorente L, Martín MM, González-Rivero AF, Ferreres J, Solé-Violán J, Labarta L, Díaz C, Jiménez A, Borreguero-León JM.

PLoS One. 2014 Oct 7;9(10):e109618. doi: 10.1371/journal.pone.0109618. eCollection 2014.

19.

Low plasma granulocyte-macrophage colony stimulating factor is an indicator of poor prognosis in sepsis.

Perry SE, Mostafa SM, Wenstone R, McLaughlin PJ.

Intensive Care Med. 2002 Jul;28(7):981-4. Epub 2002 May 28.

PMID:
12122541
20.

Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope m30 in critically ill patients.

Roth GA, Krenn C, Brunner M, Moser B, Ploder M, Spittler A, Pelinka L, Sautner T, Wolner E, Boltz-Nitulescu G, Ankersmit HJ.

Shock. 2004 Sep;22(3):218-20.

PMID:
15316390
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk